A review of regulatory filings has revealed recent stock transactions by Ingrid Delaet, Chief Regulatory Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX). According to a Form 4 filing, Ms. Delaet executed a sale of common stock valued at $354,321 and concurrently acquired common stock worth $178,664 on May 29, 2026.
The disposition involved the selling of 2,261 shares of Neurocrine Biosciences common stock. These shares were sold at a price of $156.71 per share. This specific transaction was managed by a broker following instructions outlined in a Rule 10b5-1 trading plan that Ms. Delaet initially adopted on February 27, 2026. It is noted that company policy prohibits any subsequent amendments or modifications to such established plans.
The sale price of $156.71 was observed near the stock's 52-week high of $162.39. At the time of reporting, Neurocrine Biosciences common stock was trading at $154.84. The company, a biotechnology firm with an enterprise value of $15.58 billion, currently trades at a Price-to-Earnings (P/E) ratio of 23.9.
In parallel to the sale, Ms. Delaet acquired 2,261 shares of common stock. This acquisition was facilitated by the exercise of non-qualified stock options. These options had been originally granted on January 31, 2022, and were scheduled to vest in 48 equal monthly installments starting February 28, 2022.
After completing these transactions, Ms. Delaet holds a total of 16,225 shares of Neurocrine Biosciences common stock. All reported transactions cover the period concluding on May 29, 2026.
Beyond insider activity, recent corporate news highlights several positive developments for Neurocrine Biosciences Inc. The company announced robust financial performance for the first quarter of 2026. For that quarter, earnings per share reached $1.94, which substantially surpassed the projected figure of $1.17. Furthermore, the company's revenue exceeded expectations, reaching $811 million when analysts had forecasted $766.85 million.
The corporate activity also included the completion of an acquisition from Soleno Therapeutics for a total consideration of $2.9 billion. Through this purchase, Neurocrine integrated VYKAT XR into its existing product portfolio. Goldman Sachs provided commentary on this deal, suggesting it is expected to bolster the company’s medium-term revenue growth and subsequently resumed coverage with a buy rating and a price target set at $213.00.
The positive outlook for Neurocrine Biosciences was further underscored by industry analysts' recent activity and clinical data presented. Bernstein and SocGen Group both initiated coverage on the company, assigning an outperform rating and setting respective price targets of $221.00. They cited the potential associated with the firm’s key drugs: Crenessity and Ingrezza. These two medications have loss-of-exclusivity dates set for 2035 and 2038, respectively.
In addition to analyst coverage, Neurocrine also presented compelling real-world data at the American Psychiatric Association 2026 Annual Meeting. The presentation focused on patients with mild tardive dyskinesia who were treated using INGREZZA. According to a survey administered to clinicians, a significant percentage of patients reported improvement: 96% showed some degree of improvement, and 86% reported seeing progress within four weeks following treatment initiation.
The market data reflects current trading activity for NBIX. The stock was last shown closing at $154.84. Other valuation indicators include the company's P/E ratio of 23.9, and analysis from InvestingPro suggests that NBIX may appear undervalued at its current price levels.
Risks
- The loss-of-exclusivity dates for two key drugs, Crenessity (2035) and Ingrezza (2038), represent future revenue uncertainty.
- Insider transactions, while following established plans, still reflect the current market valuation dynamics.
More from Insider Trading